Quentis Therapeutics Appoints Magram Chief Scientific Officer

Xconomy New York — 

Jeanne Magram has been appointed chief scientific officer of cancer immunotherapy developer Quentis Therapeutics. Before joining New York-based Quentis, Magram was chief scientific officer of Northern Biologics, a Toronto biotech company. Her experience also includes posts at Pfizer (NYSE: PFE) and Boeringer Ingelheim. In February, Quentis raised $48 million in a Series A financing round to back preclinical drugs intended to block a cellular stress response that disrupts the immune system’s ability to fight cancer.